Sign in to view content

ReCLAIM-2: Phase 2 Trial of Subcutaneous Elamipretide in Patients with Noncentral Geographic Atrophy

Jeffrey S. Heier, MD

Video
Published 2022

Related

Primary Analysis Results of the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) for Patients With Neovascular AMD
Peter A. Campochiaro, MD
Annual Meeting Talks
2020
Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018
Episode 196: Dr. Sharon Fekrat on vitreretinal fellow education, alpha-melanocyte stimulating hormone and more
Jayanth Sridhar, MD
Member Podcasts
2019

Category: AMD-Non-Neovascular

See more